Role of remdisivir among COVID-19 patient’s recovery
| Autor: | null Ather Mehmood, null Javaria Malik, null Attiya Hameed Khan, null Wajid Hussain, null Akhtar Ali Bandeshah, null Arsalan Abdullah, null Sehrish Zubair, null Benish Shahzadi, null Abdul Samad Abbasi |
|---|---|
| Rok vydání: | 2021 |
| Zdroj: | The Professional Medical Journal. 28:1862-1868 |
| ISSN: | 2071-7733 1024-8919 |
| DOI: | 10.29309/tpmj/2021.28.12.6787 |
| Popis: | Objective: To assess the effect of Remedisvir, its safety Profile, and efficacy among COVID-19 patients. Study Design: Retrospective Observational study. Setting: South East Hospital and Research Center, Islamabad, Pakistan. Period: December 2020 to July 2021. Material & Methods: 100 patients were included in this study who received Remedisvir infusion, day 5, 7, and 10 after admitting the hospital with COVID-19 symptoms. We infuse 200mg I/V Remedisvir in 100cc N/S followed by 100mg I/V daily into 100cc N/S. After infusion, all patients were monitored strictly. Results: The mean age of the patients was (51. 89±15.441). The outcome of Remedisvir showed that 14% improved their condition, 42% discharged with oxygen, 27% discharged without oxygen, and only 17% expired). Remedisvir showed a positive effect at (p≤0.001) among laboratory values and oxygen support category. Conclusion: When patient suffering from COVID-19 symptoms and low oxygen saturation show good clinical outcome treated with Remedisvir. According to the results of our study, it is concluded that, at present Remedisvir remains a good drug, it shows a positive effect on oxygen saturation and length of hospital stay. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|